Heterogeneity but individual constancy of epitopes, isotypes and avidity of factor H autoantibodies in atypical hemolytic uremic syndrome

Molecular Immunology

Volumn 70, Issue , 2016, Pages 47-55

  Nozal, Pilar ^a,b   Bernabéu Herrero, Maria E ^a,b   Uzonyi, Barbara ^c   Szilágyi, Ágnes ^d   Hyvärinen, Satu ^e   Prohászka, Zoltán ^d   Jokiranta, T Sakari ^e   Sánchez Corral, Pilar ^a,b   López Trascasa, Margarita ^a,b   Józsi, Mihály ^f  

^a HOSPITAL UNIVERSITARIO LA PAZ IDIPAZ   (Spain)

^b CENTRO DE INVESTIGACIÓN BIOMÉDICA EN RED DE ENFERMEDADES RARAS CIBERER   (Spain)

^c MTA ELTE Immunology Research Group Eötvös University   (Hungary)

^d SEMMELWEIS UNIVERSITY OF MEDICINE   (Hungary)

^e UNIVERSITY OF HELSINKI   (Finland)

^f EÖTVÖS LORÁND UNIVERSITY   (Hungary)

Author keywords

Atypical hemolytic uremic syndrome; Autoantibody; Autoimmunity; Avidity; Epitope mapping; Factor H

Indexed keywords

AUTOANTIBODY; COMPLEMENT FACTOR H; EPITOPE; IMMUNOGLOBULIN G; IMMUNOGLOBULIN G3; IMMUNOGLOBULIN KAPPA CHAIN; IMMUNOGLOBULIN LAMBDA CHAIN; AUTOANTIGEN; IMMUNOGLOBULIN CLASS;

ADULT; ANTIBODY BLOOD LEVEL; ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY COMPLEX; ANTIGEN BINDING; ARTICLE; CHILD; CLINICAL ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; EPITOPE MAPPING; FOLLOW UP; HEMOLYTIC UREMIC SYNDROME; HUMAN; INFANT; PRESCHOOL CHILD; PRIORITY JOURNAL; PROTEIN POLYMORPHISM; SCHOOL CHILD; ANTIBODY AFFINITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; IMMUNOLOGY; MALE;

ADULT; ANTIBODY AFFINITY; ATYPICAL HEMOLYTIC UREMIC SYNDROME; AUTOANTIBODIES; AUTOANTIGENS; CHILD; CHILD, PRESCHOOL; COMPLEMENT FACTOR H; ENZYME-LINKED IMMUNOSORBENT ASSAY; EPITOPE MAPPING; EPITOPES, B-LYMPHOCYTE; FEMALE; HUMANS; IMMUNOGLOBULIN G; IMMUNOGLOBULIN ISOTYPES; INFANT; MALE;

EID: 84949661472     PISSN: 01615890     EISSN: 18729142     Source Type: Journal    
DOI: 10.1016/j.molimm.2015.12.005     Document Type: Article

References (42)

1. Abarrategui-Garrido C., Martinez-Barricarte R., Lopez-Trascasa M., de Cordoba S.R., Sanchez-Corral P. Characterization of complement factor H-related (CFHR) proteins in plasma reveals novel genetic variations of CFHR1 associated with atypical hemolytic uremic syndrome. Blood 2009, 114(19):4261-4271.
2. Bhattacharjee A., Reuter S., Trojnar E., Kolodziejczyk R., Seeberger H., Hyvarinen S., Uzonyi B., Szilagyi A., Prohaszka Z., Goldman A., et al. The major autoantibody epitope on factor H in atypical hemolytic uremic syndrome is structurally different from its homologous site in factor H related protein 1 supporting a novel model for induction of autoimmunity in this disease. J. Biol. Chem. 2015, 290(15):9500-9510.
3. Blanc C., Togarsimalemath S.K., Chauvet S., Le Quintrec M., Moulin B., Buchler M., Jokiranta T.S., Roumenina L.T., Fremeaux-Bacchi V., Dragon-Durey M.A. Anti-factor H autoantibodies in C3 glomerulopathies and in atypical hemolytic uremic syndrome: one target, two diseases. J. Immunol. 2015, 194(11):5129-5138.
4. Blanc C., Roumenina L.T., Ashraf Y., Hyvarinen S., Sethi S.K., Ranchin B., Niaudet P., Loirat C., Gulati A., Bagga A., et al. Overall neutralization of complement factor H by autoantibodies in the acute phase of the autoimmune form of atypical hemolytic uremic syndrome. J. Immunol. 2012, 189(7):3528-3537.
5. Blaum B.S., Hannan J.P., Herbert A.P., Kavanagh D., Uhrin D., Stehle T. Structural basis for sialic acid-mediated self-recognition by complement factor H. Nat. Chem. Biol. 2015, 11(1):77-82.
6. Bresin E., Rurali E., Caprioli J., Sanchez-Corral P., Fremeaux-Bacchi V., Rodriguez de Cordoba S., Pinto S., Goodship T.H., Alberti M., Ribes D., et al. Combined complement gene mutations in atypical hemolytic uremic syndrome influence clinical phenotype. J. Am. Soc. Nephrol 2013, 24(3):475-486.
7. Delvaeye M., Noris M., De Vriese A., Esmon C.T., Esmon N.L., Ferrell G., Del-Favero J., Plaisance S., Claes B., Lambrechts D., et al. Thrombomodulin mutations in atypical hemolytic-uremic syndrome. N. Engl. J. Med. 2009, 361(4):345-357.
8. Diamante Chiodini B., Davin J.C., Corazza F., Khaldi K., Dahan K., Ismaili K., Adams B. Eculizumab in anti-factor h antibodies associated with atypical hemolytic uremic syndrome. Pediatrics 2014, 133(6):e1764-e1768.
9. Dragon-Durey M.A., Loirat C., Cloarec S., Macher M.A., Blouin J., Nivet H., Weiss L., Fridman W.H., Fremeaux-Bacchi V. Anti-factor H autoantibodies associated with atypical hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2005, 16(2):555-563.
10. Dragon-Durey M.A., Blanc C., Marliot F., Loirat C., Blouin J., Sautes-Fridman C., Fridman W.H., Fremeaux-Bacchi V. The high frequency of complement factor H related CFHR1 gene deletion is restricted to specific subgroups of patients with atypical haemolytic uraemic syndrome. J. Med. Genet. 2009, 46(7):447-450.
11. Dragon-Durey M.A., Blanc C., Garnier A., Hofer J., Sethi S.K., Zimmerhackl L.B. Anti-factor H autoantibody-associated hemolytic uremic syndrome: review of literature of the autoimmune form of HUS. Semin. Thromb. Hemost. 2010, 36(6):633-640.
12. Dragon-Durey M.A., Sethi S.K., Bagga A., Blanc C., Blouin J., Ranchin B., Andre J.L., Takagi N., Cheong H.I., Hari P., et al. Clinical features of anti-factor H autoantibody-associated hemolytic uremic syndrome. J. Am. Soc. Nephrol. 2010, 21(12):2180-2187.
13. Ferreira V.P., Pangburn M.K., Cortes C. Complement control protein factor H: the good, the bad, and the inadequate. Mol. Immunol. 2010, 47(13):2187-2197.
14. Goodship T.H., Pappworth I.Y., Toth T., Denton M., Houlberg K., McCormick F., Warland D., Moore I., Hunze E.M., Staniforth S.J., et al. Factor H autoantibodies in membranoproliferative glomerulonephritis. Mol. Immunol. 2012, 52(3-4):200-206.
15. Hofer J., Giner T., Jozsi M. Complement factor H-antibody-associated hemolytic uremic syndrome: pathogenesis, clinical presentation, and treatment. Semin. Thromb. Hemost. 2014, 40(4):431-443.
16. Hofer J., Janecke A.R., Zimmerhackl L.B., Riedl M., Rosales A., Giner T., Cortina G., Haindl C.J., Petzelberger B., Pawlik M., et al. Complement factor H-related protein 1 deficiency and factor H antibodies in pediatric patients with atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2013, 8(3):407-415.
17. Jokiranta T.S., Jaakola V.P., Lehtinen M.J., Parepalo M., Meri S., Goldman A. Structure of complement factor H carboxyl-terminus reveals molecular basis of atypical haemolytic uremic syndrome. EMBO J. 2006, 25(8):1784-1794.
18. Jozsi M., Tortajada A., Uzonyi B., Goicoechea de Jorge E., Rodriguez de Cordoba S. Factor H-related proteins determine complement-activating surfaces. Trends Immunol. 2015, 36(6):374-384.
19. Jozsi M., Reuter S., Nozal P., Lopez-Trascasa Sanchez-Corral M.P., Prohaszka Z., Uzonyi B. Autoantibodies to complement components in C3 glomerulopathy and atypical hemolytic uremic syndrome. Immunol. Lett. 2014, 160(2):163-171.
20. Jozsi M., Licht C., Strobel S., Zipfel S.L., Richter H., Heinen S., Zipfel P.F., Skerka C. Factor H autoantibodies in atypical hemolytic uremic syndrome correlate with CFHR1/CFHR3 deficiency. Blood 2008, 111(3):1512-1514.
21. Jozsi M., Strobel S., Dahse H.M., Liu W.S., Hoyer P.F., Oppermann M., Skerka C., Zipfel P.F. Anti factor H autoantibodies block C-terminal recognition function of factor H in hemolytic uremic syndrome. Blood 2007, 110(5):1516-1518.
22. Kavanagh D., Pappworth I.Y., Anderson H., Hayes C.M., Moore I., Hunze E.M., Bennaceur K., Roversi P., Lea S., Strain L., et al. Factor I autoantibodies in patients with atypical hemolytic uremic syndrome: disease-associated or an epiphenomenon?. Clin. J. Am. Soc. Nephrol. 2012, 7(3):417-426.
23. Lemaire M., Fremeaux-Bacchi V., Schaefer F., Choi M., Tang W.H., Le Quintrec M., Fakhouri F., Taque S., Nobili F., Martinez F., et al. Recessive mutations in DGKE cause atypical hemolytic-uremic syndrome. Nat. Genet. 2013, 45(5):531-536.
24. Loirat C., Fremeaux-Bacchi V. Atypical hemolytic uremic syndrome. Orphanet J. Rare Dis. 2011, 6(60):1172-1660.
25. Mele C., Remuzzi G., Noris M. Hemolytic uremic syndrome. Semin. Immunopathol. 2014, 36(4):399-420.
26. Moore I., Strain L., Pappworth I., Kavanagh D., Barlow P.N., Herbert A.P., Schmidt C.Q., Staniforth S.J., Holmes L.V., Ward R., et al. Association of factor H autoantibodies with deletions of CFHR1, CFHR3, CFHR4, and with mutations in CFH, CFI, CD46, and C3 in patients with atypical hemolytic uremic syndrome. Blood 2010, 115(2):379-387.
27. Nester C.M., Thomas C.P. Atypical hemolytic uremic syndrome: what is it, how is it diagnosed, and how is it treated?. Hematol. Am. Soc. Hematol. Educ. Program 2012, 2012:617-625.
28. Noone D., Waters A., Pluthero F.G., Geary D.F., Kirschfink M., Zipfel P.F., Licht C. Successful treatment of DEAP-HUS with eculizumab. Pediatr. Nephrol. 2014, 29(5):841-851.
29. Noris M., Caprioli J., Bresin E., Mossali C., Pianetti G., Gamba S., Daina E., Fenili C., Castelletti F., Sorosina A., et al. Relative role of genetic complement abnormalities in sporadic and familial aHUS and their impact on clinical phenotype. Clin. J. Am. Soc. Nephrol. 2010, 5(10):1844-1859.
30. Nozal P., Strobel S., Ibernon M., López D., Sánchez-Corral P., Rodríguez de Córdoba S., Józsi M., López-Trascasa M. Anti-factor H antibody affecting factor H cofactor activity in a patient with dense deposit disease. Clin. Kidney J. 2012, 5(2):133-136.
31. Oppermann M., Manuelian T., Józsi M., Brandt E., Jokiranta T.S., Heinen S., Meri S., Skerka C., Götze O., Zipfel P.F. The C-terminus of complement regulator Factor H mediates target recognition: evidence for a compact conformation of the native protein. Clin. Exp. Immunol. 2006, 144(2):342-352.
32. Pickering M.C., de Jorge E.G., Martinez-Barricarte R., Recalde S., Garcia-Layana A., Rose K.L., Moss J., Walport M.J., Cook H.T., de Cordoba S.R., et al. Spontaneous hemolytic uremic syndrome triggered by complement factor H lacking surface recognition domains. J. Exp. Med. 2007, 204(6):1249-1256.
33. Prodinger W.M., Hellwage J., Spruth M., Dierich M.P., Zipfel P.F. The C-terminus of factor H: monoclonal antibodies inhibit heparin binding and identify epitopes common to factor H and factor H-related proteins. Biochem. J. 1998, 331(Pt 1):41-47.
34. Pullen G.R., Fitzgerald M.G., Hosking C.S. Antibody avidity determination by ELISA using thiocyanate elution. J. Immunol. Methods 1986, 86(1):83-87.
35. Rodriguez de Cordoba S., Hidalgo M.S., Pinto S., Tortajada A. Genetics of atypical hemolytic uremic syndrome (aHUS). Semin. Thromb. Hemost. 2014, 40(4):422-430.
36. Rodriguez E., Rallapalli P.M., Osborne A.J., Perkins S.J. New functional and structural insights from updated mutational databases for complement factor H, factor I, membrane cofactor protein and C3. Biosci. Rep. 2014, 34(5). 10.1042/BSR20140117.
37. Sanchez Chinchilla D., Pinto S., Hoppe B., Adragna M., Lopez L., Justa Roldan M.L., Pena A., Lopez Trascasa M., Sanchez-Corral P., Rodriguez de Cordoba S. Complement mutations in diacylglycerol kinase-epsilon-associated atypical hemolytic uremic syndrome. Clin. J. Am. Soc. Nephrol. 2014, 9(9):1611-1619.
38. Sanchez-Corral P., Melgosa M. Advances in understanding the aetiology of atypical haemolytic uraemic syndrome. Br. J. Haematol. 2010, 150(5):529-542.
39. Sinha A., Gulati A., Saini S., Blanc C., Gupta A., Gurjar B.S., Saini H., Kotresh S.T., Ali U., Bhatia D., et al. Prompt plasma exchanges and immunosuppressive treatment improves the outcomes of anti-factor H autoantibody-associated hemolytic uremic syndrome in children. Kidney Int. 2014, 85(5):1151-1160.
40. Skerka C., Chen Q., Fremeaux-Bacchi V., Roumenina L.T. Complement factor H related proteins (CFHRs). Mol. Immunol. 2013, 56(3):170-180.
41. Strobel S., Abarrategui-Garrido C., Fariza-Requejo E., Seeberger H., Sanchez-Corral P., Jozsi M. Factor H-related protein 1 neutralizes anti-factor H autoantibodies in autoimmune hemolytic uremic syndrome. Kidney Int. 2011, 80(4):397-404.
42. Suwannalai P., Scherer H.U., van der Woude D., Ioan-Facsinay A., Jol-van der Zijde C.M., van Tol M.J., Drijfhout J.W., Huizinga T.W., Toes R.E., Trouw L.A. Anti-citrullinated protein antibodies have a low avidity compared with antibodies against recall antigens. Ann. Rheum. Dis. 2011, 70(2):373-379.